RxDoctor Payments Data

Kimberly Kaye, MD

Internal Medicine · Gainesville, FLNPI 1326064791

Payments from drug & device makers

$1,749in general payments, 2019–2025

Across 100 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$281
  • AbbVie$252
  • Pfizer$245
  • Abbott$221
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$83
  • Amgen$74
  • plus $595 from 22 others

What the payments were for

  • Food & beverage$1,749100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,749 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$210,168
Medicare patients
736
Services billed
2,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$122,070
EliquisApixaban128$108,521
JardianceEmpagliflozin59$61,742
MounjaroTirzepatide31$37,131
TrulicityDulaglutide23$24,520
RybelsusSemaglutide15$17,063
Repatha PushtronexEvolocumab21$13,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,182
FarxigaDapagliflozin Propanediol13$11,463
EntrestoSacubitril/Valsartan14$11,019
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$8,436
Breo ElliptaFluticasone/Vilanterol12$7,424
Xtampza ErOxycodone Myristate14$6,512
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,338
LinzessLinaclotide12$6,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$139,133133 claims
PfizerEliquis, Abrysvo$245$112,003139 claims
Lilly USA, LLCMounjaro, Trulicity$14$61,65254 claims
AbbVieLinzess, Synthroid$252$10,06869 claims
IBSA Pharma Inc.Tirosint$14$1,97411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →